Leukemia Research Reports最新文献

{"title":"Substituting pegaspargase with recombinant Erwinia asparaginase after hypersensitivity reactions: case series of Canadian adult patients with acute lymphoblastic leukemia","authors":"Lynn Savoie,&nbsp;Kareem Jamani,&nbsp;Joseph Brandwein,&nbsp;Peng Wang","doi":"10.1016/j.lrr.2026.100610","DOIUrl":"10.1016/j.lrr.2026.100610","url":null,"abstract":"<div><div>Asparaginase treatment for acute lymphoblastic leukemia/lymphoblastic lymphoma is often discontinued or interrupted due to hypersensitivity reactions (HSRs) or silent inactivation, with inferior clinical outcomes. In those instances, consensus experts recommend switching to an immunogenically distinct asparaginase preparation. This case series details experiences of 4 adult patients who developed HSRs or silent inactivation while receiving modified Dana-Farber Cancer Institute (DFCI) protocols involving pegaspargase and consequently switched to crisantaspase (JZP458), a recombinant <em>Erwinia</em> asparaginase that was well tolerated without evidence of cross-immunological activity in 3 out of 4 cases, and with achievement of adequate serum asparaginase levels. Although limited to 4 patient cases, these data suggest that switching to crisantaspase after HSRs or silent inactivation of pegaspargase may represent a viable therapeutic option in adults, with close monitoring to ensure effective asparaginase levels. Dedicated clinical studies are needed to examine DFCI lymphoblastic leukemia protocols in more diverse patient populations.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100610"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149153588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Catch-Up Vaccinations Post-Stem Cell Transplant: A case series and review of the literature”","authors":"Rehab Mohammed Gaafar ,&nbsp;Afnan Mohsen Alamodi","doi":"10.1016/j.lrr.2026.100575","DOIUrl":"10.1016/j.lrr.2026.100575","url":null,"abstract":"<div><div>Stem cell transplantation (SCT), including autologous and allogeneic approaches, is a potentially curative therapy for various hematologic malignancies and selected non-malignant disorders. Autologous stem cell transplantation (ASCT) is an established curative treatment for hematologic malignancies, including Hodgkin lymphoma (HL). Non-Hodgkin Lymphoma (NHL), and Multiple Myeloma (MM), but infectious complications remain a major challenge. Vaccination is an essential strategy to reduce the risk of vaccine-preventable infections following transplant. This case series describes immunocompromised patients with relapsed or refractory hematologic malignancies who underwent ASCT and were referred for post-transplant immunization. We present a catch-up and COVID-19 vaccination schedule using minimum recommended intervals, with emphasis on immunocompromised hosts and post-ASCT maintenance therapies. Post-ASCT maintenance therapies such as rituximab may impair humoral responses and reduce vaccine immunogenicity; however, current guidelines support prioritized use of inactivated vaccines, including pneumococcal conjugate vaccines (PCV-13) followed by Pneumococcal Polysaccharide vaccine (PPSV-23) and annual inactivated influenza vaccination. Vaccination timing should consider B-cell–depleting therapies to optimize immune response, while live attenuated vaccines remain contraindicated during ongoing immunosuppression. Vaccines were well tolerated, with only mild injection-site reactions reported.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100575"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147656360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up","authors":"Huan Tao,&nbsp;Nenggang Jiang,&nbsp;Yongqian Jia","doi":"10.1016/j.lrr.2026.100605","DOIUrl":"10.1016/j.lrr.2026.100605","url":null,"abstract":"<div><div>Secondary pure red cell aplasia (PRCA) is one of the most common cytopenic complications in T-cell large granular lymphocyte (T-LGL) leukemia and requires therapeutic intervention. Refractory T-LGL-associated PRCA lacks a unified salvage regimen, and effective targeted agents remain scarce. In recent years, epigenetic modifications have been implicated in the pathogenesis of T-LGL leukemia, yet relevant clinical evidence is limited. We report a case of refractory T-LGL leukemia complicated by PRCA that was resistant to cyclosporine (CsA). Then the patient achieved rapid disease control with chidamide plus thalidomide in the early phase, and has maintained long-term remission for six years on chidamide monotherapy after thalidomide discontinuation. Notably, clonal T-cell receptor (TCR) variable β-chain (Vβ) 3 persisted on flow cytometry throughout the treatment course. As an epigenetic modulator, chidamide represents a more convenient and promising therapeutic strategy for managing T-LGL leukemia, prompting us to present this case.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100605"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report","authors":"Hamza Khoudari ,&nbsp;Abdalla Shoaib ,&nbsp;Muhammad Nashatizadeh ,&nbsp;Nausheen Ahmed ,&nbsp;Forat Lutfi ,&nbsp;Muhammad Mushtaq ,&nbsp;Leyla Shune ,&nbsp;Anurag Singh ,&nbsp;Sunil Abhyankar ,&nbsp;Joseph McGuirk ,&nbsp;Haitham Abdelhakim","doi":"10.1016/j.lrr.2026.100577","DOIUrl":"10.1016/j.lrr.2026.100577","url":null,"abstract":"<div><div>Anti-BCMA CAR T-cell therapy, specifically ciltacabtagene autoleucel, has significantly improved outcomes for relapsed/refractory multiple myeloma (RRMM). While early-onset immune-effector cell–associated neurotoxicity syndrome (ICANS) is a recognized complication, delayed-onset and non-ICANS neurological syndromes, such as movement and neurocognitive toxicity (MNT), present unique diagnostic and therapeutic challenges.</div><div>We report a case of a 61-year-old female with a 15-year history of RRMM who developed severe, delayed neurotoxicity 50 days after ciltacabtagene autoleucel infusion. The clinical course began with confusion and rapidly progressed to grade 4 ICANS characterized by lethargy, rigidity, and parkinsonian features. Serial MRI imaging revealed evolving, symmetric T2/FLAIR hyperintensities in the basal ganglia and brainstem, and reactive pachymeningitis. Despite aggressive multi modal immunosuppression, the patient’s condition remained refractory and expired on day 93. Post-mortem autopsy confirmed severe bilateral hippocampal sclerosis, diffuse gliosis, and microglial infiltration.</div><div>This case highlights a fatal presentation of delayed neurotoxicity that overlaps with the emerging MNT phenotype. As CAR-T therapies expand, this case underscores the necessity for prolonged clinical vigilance and the urgent need for novel management strategies for refractory, late-onset neurotoxicity.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100577"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT","authors":"Yasuyuki Takahashi ,&nbsp;Ken Naganuma ,&nbsp;Yuka Tanaka ,&nbsp;Noriyuki Sakata ,&nbsp;Taisuke Kawada ,&nbsp;Masahiro Kizaki ,&nbsp;Shuji Momose ,&nbsp;Morihiro Higashi ,&nbsp;Takayuki Tabayashi","doi":"10.1016/j.lrr.2026.100573","DOIUrl":"10.1016/j.lrr.2026.100573","url":null,"abstract":"<div><div>We report a rare phenotype of Stage IV extranodal marginal zone lymphoma (MALT lymphoma) manifesting as diffuse, asymptomatic skeletal muscle and bone marrow infiltration in a 60-year-old female. Despite a high tumor burden and intense ¹⁸F-FDG avidity (SUVmax 8.8), muscle enzymes remained normal, indicating a non-destructive \"silent infiltrator\" growth pattern. The diagnosis was confirmed via biopsy (CD20+, CD5-, CyclinD1-) and negative MYD88 L265P mutation status, excluding lymphoplasmacytic lymphoma. The patient achieved a Complete Metabolic Response following Bendamustine-Rituximab therapy. This case underscores the utility of PET/CT in detecting occult systemic disease and defines a unique, indolent clinical variant of muscular MALT lymphoma.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100573"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells","authors":"Sepideh Hassanpour Khodaei ,&nbsp;Shahnaz Sabetkam ,&nbsp;Zeinab Mazloumi ,&nbsp;Ali Rafat ,&nbsp;Diana Hekari ,&nbsp;Khadijeh Dizaji Asl","doi":"10.1016/j.lrr.2026.100570","DOIUrl":"10.1016/j.lrr.2026.100570","url":null,"abstract":"<div><div>Statins and arsenic trioxide (ATO) are known for their significant anti-neoplastic properties; however, limited research has investigated their potential synergistic effects. This study explores the individual and combined impact of ATO and atorvastatin on programmed cell death and proliferation in acute lymphoblastic leukemia (ALL) cell model. The ALL cell line was exposed to different doses of atorvastatin and ATO, both individually and in combination, to evaluate their respective IC50 values and identify the most effective concentrations. The proportions of apoptotic cells were quantified using Annexin V/PI staining, while Ki-67 expression, a well-established marker of cell proliferation, was assessed through flow cytometry. The findings revealed that atorvastatin and ATO, at concentrations of 12.4 µM and 3.34 µM, respectively, significantly enhanced apoptosis in ALL cells. Moreover, the combination therapy resulted in a marked increase in anti-proliferative effects. These findings provide new insights into the potential use of ATO and atorvastatin as a combined therapeutic strategy, highlighting their promise as a novel approach in the treatment of ALL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100570"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147656359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study","authors":"Sinem Namdaroğlu,&nbsp;Hikmetullah Batgi,&nbsp;Merve Kakcı,&nbsp;Osman Can Öztürk,&nbsp;Ömer Şeker,&nbsp;Berna Güzel,&nbsp;Kardelen Tayfur,&nbsp;Semih Başcı","doi":"10.1016/j.lrr.2026.100584","DOIUrl":"10.1016/j.lrr.2026.100584","url":null,"abstract":"<div><h3>Background</h3><div>Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging, and achieving metabolic complete response prior to autologous stem cell transplantation (ASCT) is important. GDP is a generally well-tolerated outpatient regimen, while brentuximab vedotin (BV) has demonstrated encouraging activity in salvage combinations. Adult real-world data on BV+GDP remain limited.</div></div><div><h3>Methods</h3><div>Eight adult R/R cHL patients received BV+GDP between May 2023 and March 2025. Responses (Lugano 2014), toxicities (CTCAE v5.0), and mobilization outcomes were retrospectively evaluated.</div></div><div><h3>Results</h3><div>Complete response was achieved in 7/8 patients (87.5%). All responders underwent successful stem-cell mobilization and ASCT. Toxicities were manageable, with no febrile neutropenia or renal toxicity observed. At a median follow-up of 10.6 months, all patients remained alive and progression-free.</div></div><div><h3>Conclusion</h3><div>BV+GDP showed encouraging activity with acceptable tolerability, supporting further prospective evaluation.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100584"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147746586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric AML in Sousse, Tunisia: Epidemiologic patterns and hierarchical prognostic factors","authors":"Donia Bouhoula,&nbsp;Haifa Regaieg,&nbsp;Hela Abroug,&nbsp;Nesrine Ben Sayed,&nbsp;Yossra Ben Youssef","doi":"10.1016/j.lrr.2025.100556","DOIUrl":"10.1016/j.lrr.2025.100556","url":null,"abstract":"<div><div>Pediatric acute myeloid leukemia outcomes in resource-limited regions remain understudied, particularly regarding how regional epidemiologic patterns interact with prognostic determinants. Our Tunisian cohort (n=68) reveals distinct pediatric AML features: older presentation (median 11 years), male predominance (63%), and unexpected AML2 subtype prevalence (35%). Cytogenetics showed 24% favorable-risk and 22% adverse-risk cases. Treatment outcomes correlated strongly with risk stratification, emphasizing the need for adapted diagnostic protocols in resource-conscious settings to optimize care pathways.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100556"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of clinical efficacy and safety of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly","authors":"Yanxia He,&nbsp;Lili Zhang,&nbsp;Mengmeng Liu,&nbsp;Fuhua Zhang,&nbsp;Hui Gao","doi":"10.1016/j.lrr.2025.100559","DOIUrl":"10.1016/j.lrr.2025.100559","url":null,"abstract":"<div><h3>Objective</h3><div>To systematically evaluate the clinical efficacy and safety of decitabine (DAC) combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia (AML) using meta-analysis</div></div><div><h3>Methods</h3><div>The studies reported the clinical efficacy and safety of DAC combined with CAG regimen in the treatment of elderly AML patients were searched in Pubmed, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP database by computer. On the basis of the screening criteria, the non-conforming literature was eliminated and the final selected literature was analyzed. The methodological quality was assessed and the research data was extracted. Revman 5.3 software was used to assess the clinical efficacy and safety of DAC combined with CAG in the treatment of elderly AML patients, which were shown with forest map. The funnel plots were used to test publication bias.</div></div><div><h3>Results</h3><div>Thirteen studies involving 1133 elderly AML patients were included. ‌Meta-analysis demonstrated that‌ in comparison with CAG alone group, the CR rate (<em>Z</em> = 5.50, <em>P</em> &lt; 0.001) and total effective rate (<em>Z</em> = 8.71, <em>P</em> &lt; 0.001) of DAC combined with CAG group were higher, while there was no significant difference in PR rate between the two groups (<em>Z</em> = 1.59, <em>P</em> = 0.11). And the infection rate (<em>Z</em> = 3.56, <em>P</em> &lt; 0.001) and fever rate (<em>Z</em> = 5.86, <em>P</em> &lt; 0.001) of DAC combined with CAG group were increased. There were no significant differences in the rates of hematological adverse reactions (<em>P</em> = 0.14), gastrointestinal reactions (<em>P</em> = 0.05), alopecia (<em>P</em> = 0.39), heart injury (<em>P</em> = 0.55), liver and kidney injury (<em>P</em> = 0.74) and myelosuppression (<em>P</em> = 0.82) between the two groups.</div></div><div><h3>Conclusion</h3><div>Compared with CAG alone regimen, DAC combined with CAG regimen improves clinical efficacy in elderly AML patients, but increases risks of infection and fever-related adverse events.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100559"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of SLAMF7 on hairy cell leukemia indicates therapy option with SLAMF7-antibody Elotuzumab","authors":"Anju Singh,&nbsp;Mathis Bittermann,&nbsp;Ibrahim Hammada,&nbsp;Simon Weisemann,&nbsp;Mathias Vierbuchen,&nbsp;Ahmet H. Elmaagacli","doi":"10.1016/j.lrr.2026.100576","DOIUrl":"10.1016/j.lrr.2026.100576","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100576"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}